EU Traditional Herbal Registration Scheme Opens Market For Qualified TCM Products
- 时间：
- 浏览：0
- 来源：TCM1st
Let’s cut through the noise: if you’re a TCM manufacturer, exporter, or regulatory consultant eyeing the EU — the Traditional Herbal Registration (THR) scheme isn’t just paperwork. It’s your *legitimacy passport*. Since 2004, over 320 THR licenses have been granted by the UK MHRA and EU national authorities — and yes, more than 42% of those approved products contain herbs with documented use in classical Chinese medicine (e.g., *Ginkgo biloba*, *Panax ginseng*, *Zingiber officinale*) [source: EMA Annual Report 2023].
But here’s what most miss: THR doesn’t require clinical trials — it hinges on *30+ years of documented traditional use*, with at least 15 years inside the EU/EEA. That means well-documented TCM formulas *with verifiable historical trade records* (e.g., German or Dutch import logs from the 1980s–90s) can qualify faster than novel botanicals.
Here’s how the bar actually sits today:
| Requirement | THR Standard | TCM-Friendly Gap? |
|---|---|---|
| Minimum traditional use period | 30 years total, ≥15 in EU/EEA | ✅ Yes — many classics (e.g., Liu Wei Di Huang Wan variants) meet this via EU-based TCM clinics since 1990s |
| Quality control | Ph. Eur. or ISO-compliant testing | ⚠️ Needs adaptation — but 68% of THR-approved TCM products now use HPLC fingerprinting aligned with both Ph. Eur. and Chinese Pharmacopoeia 2020 |
| Labeling claims | Only traditional-use indications (e.g., “traditionally used to support digestion”) | ✅ Fully compatible — no pharmacological claims needed |
Bottom line? THR isn’t a barrier — it’s a filter. And right now, only ~12% of eligible TCM products in circulation hold THR status. That’s not failure. That’s opportunity.
If your formula has consistent EU distribution history, GMP-compliant manufacturing (EU or WHO-GMP recognized), and transparent herb sourcing — you’re likely 6–9 months away from market access. Start with a qualified EU Responsible Person (RP), conduct a gap analysis against THR eligibility criteria, and prioritize products with existing monographs (e.g., Commission E or ESCOP listings). No speculation. Just precedent, proof, and precision.